<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M858</article-id>
      <article-id pub-id-type="publisher-id">molbank-2015-M858</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>2-Fluoro-<italic>N</italic>-methyl-<italic>N</italic>-({(3<italic>S</italic>,4<italic>S</italic>)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1<italic>H</italic>-isochromen-3-yl}methyl)ethanamine</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Neudorfer</surname>
            <given-names>Catharina</given-names>
          </name>
          <xref rid="af1-molbank-2015-M858" ref-type="aff">1</xref>
          <xref rid="af2-molbank-2015-M858" ref-type="aff">2</xref>
          <xref rid="c1-molbank-2015-M858" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shanab</surname>
            <given-names>Karem</given-names>
          </name>
          <xref rid="af1-molbank-2015-M858" ref-type="aff">1</xref>
          <xref rid="af2-molbank-2015-M858" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holzer</surname>
            <given-names>Wolfgang</given-names>
          </name>
          <xref rid="af2-molbank-2015-M858" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rami-Mark</surname>
            <given-names>Christina</given-names>
          </name>
          <xref rid="af1-molbank-2015-M858" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mitterhauser</surname>
            <given-names>Markus</given-names>
          </name>
          <xref rid="af1-molbank-2015-M858" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wadsak</surname>
            <given-names>Wolfgang</given-names>
          </name>
          <xref rid="af1-molbank-2015-M858" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Spreitzer</surname>
            <given-names>Helmut</given-names>
          </name>
          <xref rid="af2-molbank-2015-M858" ref-type="aff">2</xref>
          <xref rid="c1-molbank-2015-M858" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Haider</surname>
            <given-names>Norbert</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2015-M858"><label>1</label>Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; E-Mails: <email>karem.shanab@gmail.com</email> (K.S.); <email>christina.rami-mark@meduniwien.ac.at</email> (C.R.-M.); <email>markus.mitterhauser@meduniwien.ac.at</email> (M.M.); <email>wolfgang.wadsak@meduniwien.ac.at</email> (W.W.)</aff>
      <aff id="af2-molbank-2015-M858"><label>2</label>Division of Drug Synthesis, Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstra&#xDF;e 14, 1090 Vienna, Austria; E-Mail: <email>wolfgang.holzer@univie.ac.at</email></aff>
      <author-notes>
        <corresp id="c1-molbank-2015-M858"><label>*</label> Authors to whom correspondence should be addressed; E-Mails: <email>catharina.neudorfer@gmail.com</email> (C.N.); <email>helmut.spreitzer@univie.ac.at</email> (H.S.); Tel.: +43-4277-55629 (C.N.); +43-4277-55621 (H.S.); Fax: +43-4277-855629 (C.N.); +43-4277-855621 (H.S.).</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>08</day>
        <month>05</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>06</month>
        <year>2015</year>
      </pub-date>
      <volume>2015</volume>
      <issue>2</issue>
      <elocation-id>M858</elocation-id>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>04</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>06</day>
          <month>05</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>Starting from <italic>N</italic>-methyl-1-{(3<italic>S</italic>,4<italic>S</italic>)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1<italic>H</italic>-isochromen-3-yl}methanamine (<bold>1</bold>) target compound <bold>2</bold> is prepared using a mild, direct alkylation approach with 2-fluoroethyl trifluoromethanesulfonate.</p>
      </abstract>
      <kwd-group>
        <kwd>NET</kwd>
        <kwd>PET</kwd>
        <kwd>PHOXI</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Since norepinephrine (NE) represents a fundamental neurochemical messenger, its accurate regulation is of major importance. Thus the norepinephrine transporter (NET), responsible for the NE equilibrium in the synaptic cleft, is considered to be involved in a variety of neurological/psychiatric disorders [<xref ref-type="bibr" rid="B1-molbank-2015-M858">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2015-M858">2</xref>], but also plays a pivotal role in cardiovascular [<xref ref-type="bibr" rid="B1-molbank-2015-M858">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2015-M858">2</xref>,<xref ref-type="bibr" rid="B3-molbank-2015-M858">3</xref>], and metabolic diseases [<xref ref-type="bibr" rid="B3-molbank-2015-M858">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2015-M858">4</xref>,<xref ref-type="bibr" rid="B5-molbank-2015-M858">5</xref>].</p>
      <p>To obtain information about the transporter abundance and density in healthy and pathological living human brains, the most suitable and accurate technique today is positron emission tomography (PET). It represents a non-invasive molecular imaging technique and a suitable approach towards the collection of missing data in the living organism. Moreover, it enables direct quantification of receptor or transporter densities <italic>in vivo</italic>. However, in order to understand the molecular changes of the noradrenergic system via PET, prior suitable NET-PET radioligands need to be prepared. Non-radioactive reference compounds serve as a basis for preclinical investigations of the respective target.</p>
      <p>In this regard, several 3,4-dihydro-1<italic>H</italic>-isochromene derivatives were synthesized [<xref ref-type="bibr" rid="B6-molbank-2015-M858">6</xref>,<xref ref-type="bibr" rid="B7-molbank-2015-M858">7</xref>], which have been described by our research group as potential precursors and reference compounds for PET based investigations of the NET. In continuation of these previous studies, we are reporting in this paper the synthesis of 2-fluoro-<italic>N</italic>-methyl-<italic>N</italic>-{[(3<italic>S</italic>,4<italic>S</italic>)-4-(2-methylphenoxy)-3,4-dihydro-1<italic>H</italic>-isochromen-3-yl]methyl}ethanamine (FE@PHOXI2) (<bold>3</bold>), a reference  compound  for  the  NET  for  future preclinical testing.</p>
    </sec>
    <sec>
      <title>Results and Discussion</title>
      <p>Derivative <bold>1</bold> was made accessible by reacting 1<italic>H</italic>-isochromen-4(3<italic>H</italic>)-one in a Mannich reaction with dimethylamine hydrochloride and paraformaldehyde, followed by reduction of the keto group into an alcohol group with L-Selectride. Subsequent reaction with 1-fluoro-2-(trifluoromethyl)benzene then afforded <italic>N</italic>,<italic>N</italic>-dimethyl-1-{(3<italic>S</italic>,4<italic>S</italic>)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1<italic>H</italic>-isochromen-3-yl}methanamine, which after <italic>N</italic>-demethylation yielded compound <bold>1</bold>.</p>
      <p>For the preparation of derivative <bold>2</bold>, a mild synthesis approach was chosen, in which freshly prepared 2-fluoroethyl trifluoromethanesulfonate [<xref ref-type="bibr" rid="B8-molbank-2015-M858">8</xref>] was reacted with the -prior activated-secondary amine (<bold>1</bold>) at 0 &#xB0;C (<xref ref-type="scheme" rid="molbank-2015-M858-sch001">Scheme 1</xref>). Due to the high reactivity of triflates, the alkylation was carried out in less than ten minutes while the temperature was slowly raised to 25 &#xB0;C.</p>
    </sec>
    <sec>
      <title>Experimental Section</title>
      <sec>
        <title>General Information</title>
        <p>The NMR spectra were recorded from a CDCl<sub>3</sub> solution on a Bruker Avance III 400 spectrometer (Billerica, MA, USA) (400 MHz for <sup>1</sup>H, 100 MHz for <sup>13</sup>C, 40 MHz for <sup>15</sup>N, 376 MHz for <sup>19</sup>F) at 25 &#xB0;C. The center of the solvent (residual) signal was used as an internal standard which was related to TMS with &#x3B4; 7.26 ppm (<sup>1</sup>H in CDCl<sub>3</sub>), and &#x3B4; 77.0 ppm (<sup>13</sup>C in CDCl<sub>3</sub>). <sup>19</sup>F-NMR spectra were referenced by absolute referencing via <italic>&#x39E;</italic> ratio. Digital resolutions were 0.25 Hz/data point in the <sup>1</sup>H and 0.3 Hz/data point in the <sup>13</sup>C-NMR spectra. Coupling constants (<italic>J</italic>) are quoted in Hz. The following abbreviations were used to show the multiplicities: s: singlet, d: doublet, t: triplet, q: quadruplet, dd: doublet of doublet, m: multiplet. Mass spectra were obtained on a Shimadzu QP 1000 instrument (Kyoto, Japan, EI, 70 eV), high-resolution mass spectrometry (HRMS) was carried out on a maXis HD ESI-Qq-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) in the positive-ion mode by direct infusion. Compound purity: all compounds synthesized featured a purity of at least 95%.</p>
      </sec>
      <sec id="sec2-molbank-2015-M858">
        <title>2-Fluoro-N-methyl-N-{[(3S,4S)-4-(2-(trifluoromethyl)phenoxy)-3,4-dihydro-1H-isochromen-3-yl]methyl}ethanamine (FE@PHOXI2)</title>
        <p>To a suspension of <italic>N</italic>-methyl-1-((3<italic>S</italic>,4<italic>S</italic>)-4-(2-(trifluoromethyl)phenoxy)-3,4-dihydro-1<italic>H</italic>-isochromen-3-yl)methanamine (0.07 g, 0.22 mmol) in dry ACN (5 mL) was added triethylamine (0.05 mL, 0.33 mmol) under argon atmosphere. After cooling the mixture to 0 &#xB0;C, 2-fluoroethyl trifluoromethansulfonate (0.03 mL, 0.26 mmol) was slowly added. The solution was stirred for 10 min during which the temperature was allowed to warm to 20 &#xB0;C. After evaporation of the solvent, the crude reaction product was purified by column chromatography (silica gel 60, 7% MeOH in CH<sub>2</sub>Cl<sub>2</sub>).</p>
        <p>Yield: 55 mg (65%), light yellow oil.</p>
        <p><sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): &#x3B4; (ppm) 2.42 (s, 3H, CH<sub>2</sub>NC<underline>H<sub>3</sub></underline>CH<sub>2</sub>CH<sub>2</sub>F), 2.73&#x2013;2.75 (m, 1H, CH<sub>2</sub>NCH<sub>3</sub>C<underline>H</underline><sub>2</sub>CH<sub>2</sub>F), 2.85 (dd, <italic>J</italic> = 13.3 Hz and 6.6 Hz, 1H, C<underline>H</underline><sub>2</sub>NCH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>F), 2.88&#x2013;2.91 (m, 1H, CH<sub>2</sub>NCH<sub>3</sub>C<underline>H</underline><sub>2</sub>CH<sub>2</sub>F) 2.98 (dd, <italic>J</italic> = 13.3 Hz and 6.4 Hz, 1H, C<underline>H</underline><sub>2</sub>NCH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>F), 4.12 (dt, <italic>J</italic> = 2.3 Hz and 6.5 Hz, 1H, isochr 3-C<underline>H</underline>), 4.46 (t, <italic>J</italic> = 4.9 Hz, 1H, CH<sub>2</sub>NCH<sub>3</sub>CH<sub>2</sub>C<underline>H</underline><sub>2</sub>F), 4.58 (t, <italic>J</italic> = 4.9 Hz, 1H, CH<sub>2</sub>NCH<sub>3</sub>CH<sub>2</sub>C<underline>H</underline><sub>2</sub>F), 4.87 (d, <italic>J</italic> = 15.3 Hz, AB-system, 1H, isochr 1-C<underline>H</underline><sub>2</sub>), 5.05 (d, <italic>J</italic> = 15.3 Hz, AB-system, 1H, isochr 1-C<underline>H</underline><sub>2</sub>), 5.50 (d, <italic>J</italic> = 2.3 Hz, 1H, isochr 4-C<underline>H</underline>), 7.00&#x2013;7.04 (m, 1H, benz 4-C<underline>H</underline>), 7.07&#x2013;7.12 (m, 3H, isochr 8-C<underline>H</underline>, isochr 5-C<underline>H</underline>, isochr 6-C<underline>H</underline>), 7.26&#x2013;7.30 (m, 1H, isochr 7-C<underline>H</underline>), 7.35&#x2013;7.37 (m, 1H, isochr-6-C<underline>H</underline>), 7.46&#x2013;7.51 (m, 1H, benz 5-C<underline>H</underline>), 7.52&#x2013;7.54 (m, 1H, benz 3-C<underline>H</underline>).</p>
        <p><sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): &#x3B4; (ppm) 43.4 (CH<sub>2</sub>N<underline>C</underline>H<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>F), 57.4 (<underline>C</underline>H<sub>2</sub>NCH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>F), 57.9 (d, <italic>J</italic> = 19.8 Hz, CH<sub>2</sub>NCH<sub>3</sub><underline>C</underline>H<sub>2</sub>CH<sub>2</sub>F), 67.3 (isochr 1-<underline>C</underline>H<sub>2</sub>), 72.7 (isochr 4-<underline>C</underline>H), 74.6 (isochr 3-<underline>C</underline>H), 81.8 (d, <italic>J</italic> = 167.8 Hz, CH<sub>2</sub>NCH<sub>3</sub>CH<sub>2</sub><underline>C</underline>H<sub>2</sub>F), 116.4 (benz 6-<underline>C</underline>H), 120.6 (q, <italic>J</italic> = 30.5 Hz, benz 2-C), 120.8 (benz 4-<underline>C</underline>H), 123.5 (q, <italic>J</italic> = 272.6 Hz, benz <underline>C</underline>F<sub>3</sub>), 124.3 (isochr 8-<underline>C</underline>H), 126.5 (isochr 6-<underline>C</underline>H), 127.2 (q, <italic>J</italic> = 5.3 Hz, benz 3-<underline>C</underline>H), 128.7 (isochr 7-<underline>C</underline>H), 128.9 (isochr 5-<underline>C</underline>H), 131.2 (isochr 4a-C), 132.9 (benz 5-<underline>C</underline>H), 135.3 (isochr 8a-C), 155.9 (q, <italic>J</italic> = 1.7 Hz, benz 1-C).</p>
        <p><sup>19</sup>F-NMR (471 MHz, CDCl<sub>3</sub>): &#x3B4; (ppm) &#x2212;61.8 (s, benz C<underline>F</underline>), &#x2212;219.3 (m, CH<sub>2</sub>NCH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub><underline>F</underline>).</p>
        <p>MS: <italic>m/z</italic> (%) 383 (M<sup>+</sup>, 1), 350 (1), 322 (1), 218 (1), 175 (1), 132 (4), 115 (3), 104 (4), 90 (100).</p>
        <p>HRMS: <italic>m/z</italic> calculated for C<sub>20</sub>H<sub>22</sub>F<sub>4</sub>NO<sub>2</sub> [M+H]<sup>+</sup>: 384.1581. Found: 384.1532.</p>
      </sec>
    </sec>
  </body>
  <back>
    <app-group>
    <app id="app1-molbank-2015-M858">
      <title>Supplementary Materials</title>
	  <supplementary-material id="molbank-2015-M858-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M858-s001.pdf"><label>Supplementary File 1</label></supplementary-material>
	  <supplementary-material id="molbank-2015-M858-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M858-s002-mod.mol"><label>Supplementary File 2</label></supplementary-material>
	  <supplementary-material id="molbank-2015-M858-s003" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M858-s002.mol"><label>Supplementary File 3</label></supplementary-material>
    </app>
    </app-group>
    <notes>
      <title>Author Contributions</title>
      <p>Catharina Neudorfer: Responsible for the performance of the syntheses and writing; Karem Shanab: Contributions to syntheses and experimental procedures; Wolfgang Holzer: Performance of the NMR analyses; Christina Rami-Mark: Designed parts of the research; Markus Mitterhauser: Designed parts of the research and proofread the manuscript; Wolfgang Wadsak: Designed parts of the research and proofread the manuscript; Helmut Spreitzer: Conceived and supervised the syntheses.</p>
    </notes>
    <notes>
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2015-M858">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sung</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Apparsundram</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Galli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kahlig</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Savchenko</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Schroeter</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Quick</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Blakely</surname>
              <given-names>R.D.</given-names>
            </name>
          </person-group>
          <article-title>A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity</article-title>
          <source>J. Neurosci.</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>1697</fpage>
          <lpage>1709</lpage>
          <pub-id pub-id-type="pmid">12629174</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2015-M858">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Joung</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Steele</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Mazei-Robinson</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Gizer</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Teicher</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>D.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2006</year>
          <volume>103</volume>
          <fpage>19164</fpage>
          <lpage>19169</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0510836103</pub-id>
          <pub-id pub-id-type="pmid">17146058</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2015-M858">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hahn</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Blakely</surname>
              <given-names>R.D.</given-names>
            </name>
          </person-group>
          <article-title>A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters</article-title>
          <source>J. Neurosci.</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>4470</fpage>
          <lpage>4478</lpage>
          <pub-id pub-id-type="pmid">12805287</pub-id>
        </citation>
      </ref>
      <ref id="B4-molbank-2015-M858">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mirbolooki</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Upadhyay</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Constantinescu</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Mukherjee</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Adrenergic pathway activation enhances brown adipose tissue metabolism: A [<sup>18</sup>F]FDG PET/CT study in mice</article-title>
          <source>Nucl. Med. Biol.</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>10</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nucmedbio.2013.08.009</pub-id>
          <pub-id pub-id-type="pmid">24090673</pub-id>
        </citation>
      </ref>
      <ref id="B5-molbank-2015-M858">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Yeckel</surname>
              <given-names>C.W.</given-names>
            </name>
            <name>
              <surname>Weinzimmer</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mulnix</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gallezot</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Carson</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Sherwin</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>Y.S.</given-names>
            </name>
          </person-group>
          <article-title><italic>Ex vivo</italic> and <italic>in vivo</italic> Evaluation of the Norepinephrine Transporter Ligand [<sup>11</sup>C]MRB for Brown Adipose Tissue Imaging</article-title>
          <source>Nucl. Med. Biol.</source>
          <year>2012</year>
          <volume>39</volume>
          <fpage>1081</fpage>
          <lpage>1086</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nucmedbio.2012.04.005</pub-id>
          <pub-id pub-id-type="pmid">22595487</pub-id>
        </citation>
      </ref>
      <ref id="B6-molbank-2015-M858">
        <label>6.</label>
        <citation citation-type="thesis">
          <person-group person-group-type="author">
            <name>
              <surname>Neudorfer</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Development of Novel Precursors and Reference Compounds for PET Based Investigations Targeting the Norepinephrine Transporter and Monoamine Oxidase B</article-title>
          <source>Ph.D. Thesis</source>
          <publisher-name>University of Vienna</publisher-name>
          <publisher-loc>Vienna, Austria</publisher-loc>
          <month>November</month>
          <year>2014</year>
        </citation>
      </ref>
      <ref id="B7-molbank-2015-M858">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hudson</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kiankarimi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Eccles</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Mostofi</surname>
              <given-names>Y.S.</given-names>
            </name>
            <name>
              <surname>Genicot</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Dwight</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Fleck</surname>
              <given-names>B.A.</given-names>
            </name>
            <name>
              <surname>Gogas</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wade</surname>
              <given-names>W.S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>4495</fpage>
          <lpage>4498</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2008.07.050</pub-id>
          <pub-id pub-id-type="pmid">18667309</pub-id>
        </citation>
      </ref>
      <ref id="B8-molbank-2015-M858">
        <label>8.</label>
        <citation citation-type="patent">
          <person-group person-group-type="author">
            <name>
              <surname>Claremon</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Zhuang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Leftheris</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tice</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>S.B.</given-names>
            </name>
            <name>
              <surname>Cacatian</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Himmelsbach</surname>
              <given-names>F.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclic Inhibitors of 11beta-Hydroxysteroid Dehydrogenase 1</article-title>
          <source>PCT Int. Appl.</source>
          <patent>WO 2009134392 A1</patent>
          <month>November</month>
          <year>2009</year>
        </citation>
      </ref>
    </ref-list>
    <sec sec-type="display-objects">
      <title>Scheme</title>
      <fig id="molbank-2015-M858-sch001" position="float">
        <object-id pub-id-type="pii">molbank-2015-M858-sch001_Scheme 1</object-id>
        <label>Scheme 1</label>
        <caption>
          <p>Reaction of <italic>N</italic>-methyl-1-((3<italic>S</italic>,4<italic>S</italic>)-4-(2-(trifluoromethyl)phenoxy)-3,4-dihydro-1<italic>H</italic>-isochromen-3-yl)methanamine to 2-Fluoro-<italic>N</italic>-methyl-<italic>N</italic>-(((3<italic>S</italic>,4<italic>S</italic>)-4-(2-(trifluoromethyl) phenoxy)-3,4-dihydro-1<italic>H</italic>-isochromen-3-yl)methyl)ethanamine (FE@PHOXI2).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M858-sch001.tif"/>
      </fig>
    </sec>
  </back>
</article>
